Key result
Nebivolol/valsartan single-pill combination demonstrated significantly greater blood pressure-reducing efficacy compared to component monotherapies in patients with stage 1 and 2 hypertension.
Why the study?
Does the single-pill combination of nebivolol and valsartan improve blood pressure reduction in patients with stages I-II hypertension?
Does the single-pill combination of nebivolol and valsartan improve blood pressure reduction in patients with stages I-II hypertension?
The single-pill combination of nebivolol and valsartan provides an efficacious and well-tolerated treatment option for hypertension, overcoming previous concerns about combining beta-blockers and RAAS inhibitors.
Supports nebivolol/valsartan SPC consideration in stage I-II hypertension; leaves open long-term outcome data versus alternatives.
: To treat hypertension, combining two or more antihypertensive drugs from different classes is often necessary. β-Blockers and renin-angiotensin-aldosterone system inhibitors, when combined, have been deemed 'less effective' based on partially overlapping mechanisms of action and limited evidence. Recently, the single-pill combination (SPC) of nebivolol (Neb) 5 mg - a vasodilatory β1-selective antagonist/β3 agonist - and valsartan 80 mg, an angiotensin II receptor blocker, was US Food and Drug Administration-approved for hypertension. Pharmacological profiles of Neb and valsartan, alone and combined, are well characterized. In addition, a large 8-week randomized trial in stages I-II hypertensive patients (N = 4161) demonstrated greater blood pressure-reducing efficacy for Neb/valsartan SPCs than component monotherapies with comparable tolerability. In a biomarkers substudy (N = 805), Neb/valsartan SPCs prevented valsartan-induced increases in plasma renin, and a greater reduction in plasma aldosterone was observed with the highest SPC dose vs. valsartan 320 mg/day. This review summarizes preclinical and clinical evidence supporting Neb/valsartan as an efficacious and well tolerated combination treatment for hypertension.
No takes yet. Share an insight, caveat, or question.
Giles et al. (2017) conducted a review in Hypertension (n=4,161). Nebivolol/valsartan single-pill combination vs. Nebivolol monotherapy, valsartan monotherapy, or placebo was evaluated on Diastolic blood pressure (DBP) reduction from baseline. Nebivolol/valsartan single-pill combination demonstrated significantly greater blood pressure-reducing efficacy compared to component monotherapies in patients with stage 1 and 2 hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: